Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer

por Hobbs, Evthokia A., Chen, Natalie, Kuriakose, Alphi, Bonefas, Elizabeth, Lim, Bora
Publicado 2022

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer

por West, Malinda T, Goodyear, Shaun M, Hobbs, Evthokia A, Kaempf, Andy, Kartika, Thomas, Ribkoff, Jessica, Chun, Brie, Mitri, Zahi I
Publicado 2023

Impact of TP53 mutations in Triple Negative Breast Cancer

por Mitri, Zahi I., Abuhadra, Nour, Goodyear, Shaun M., Hobbs, Evthokia A., Kaempf, Andy, Thompson, Alastair M., Moulder, Stacy L.
Publicado 2022

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-...

por Hurvitz, Sara, Singh, Rashi, Adams, Brad, Taguchi, Julie A., Chan, David, Dichmann, Robert A., Castrellon, Aurelio, Hu, Eddie, Berkowitz, Jonathan, Mani, Aruna, DiCarlo, Brian, Callahan, Rena, Smalberg, Ira, Wang, Xiaoyan, Meglar, Ivana, Martinez, Diego, Hobbs, Evthokia, Slamon, Dennis J.
Publicado 2018